TOT BIOPHARM International Past Earnings Performance
Past criteria checks 0/6
TOT BIOPHARM International has been growing earnings at an average annual rate of 34.7%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 69% per year.
Key information
34.7%
Earnings growth rate
48.4%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 69.0% |
| Return on equity | -5.5% |
| Net Margin | -4.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?
Mar 18
There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues
Dec 28Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?
Nov 23We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt
May 18Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Jul 27An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued
Mar 26Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Feb 03Revenue & Expenses BreakdownBeta
How TOT BIOPHARM International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 781 | -38 | 521 | 104 |
| 30 Sep 23 | 684 | -44 | 461 | 117 |
| 30 Jun 23 | 588 | -49 | 400 | 131 |
| 31 Mar 23 | 515 | -50 | 333 | 141 |
| 31 Dec 22 | 442 | -50 | 267 | 151 |
| 30 Sep 22 | 339 | -106 | 202 | 174 |
| 30 Jun 22 | 235 | -162 | 137 | 196 |
| 31 Mar 22 | 156 | -212 | 108 | 205 |
| 31 Dec 21 | 76 | -261 | 79 | 215 |
| 30 Sep 21 | 54 | -268 | 76 | 220 |
| 30 Jun 21 | 33 | -274 | 73 | 225 |
| 31 Mar 21 | 28 | -281 | 73 | 230 |
| 31 Dec 20 | 22 | -288 | 73 | 235 |
| 30 Sep 20 | 28 | -301 | 93 | 225 |
| 30 Jun 20 | 34 | -313 | 113 | 215 |
| 31 Mar 20 | 40 | -306 | 120 | 203 |
| 31 Dec 19 | 45 | -299 | 127 | 191 |
| 31 Dec 18 | 39 | -268 | 94 | 189 |
| 31 Dec 17 | 52 | -149 | 53 | 106 |
Quality Earnings: 1875 is currently unprofitable.
Growing Profit Margin: 1875 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1875 is unprofitable, but has reduced losses over the past 5 years at a rate of 34.7% per year.
Accelerating Growth: Unable to compare 1875's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1875 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 1875 has a negative Return on Equity (-5.5%), as it is currently unprofitable.